Tüdőrák: vizsgálatok itt: Szlovákia
6 trials · From ClinicalTrials.gov, checked 2026. november 10.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Where
- Bratislava, Michalovce, Nové Zámky
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Pfizer
See details and how to joinNCT07144280 · EU 2025-521281-97-00 - 3. fázisTaking peopleA Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Poprad, Trnava
- Életkor
- 18 év and over
- People
- 444 worldwide
- Run by
- Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00 - 3. fázisTaking peopleStudy of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Where
- Banská Bystrica, Bratislava, Košice
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06890598 · EU 2024-512302-25-00 - 3. fázisTaking peopleA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Where
- Banska Bystrica
- Életkor
- 18 év and over
- People
- 768 worldwide
- Run by
- AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00 - 1/2. fázisTaking peopleStudy to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Where
- Bratislava, Nové Zámky, Poprad
- Életkor
- 18 év and over
- People
- 430 worldwide
- Run by
- Pfizer
See details and how to joinNCT04557449 · EU 2024-512120-11-00 - 3. fázisTaking peopleThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Where
- Bratislava, Komarno, Košice, Nové Zámky, Poprad, Trnava
- Életkor
- 18 év and over
- People
- 714 worldwide
- Run by
- Pfizer
See details and how to joinNCT06758401 · EU 2024-517968-36-00